BURLINGTON, Mass., Nov. 12, 2010 /PRNewswire/ — InfraReDx, Inc., a medical
device company developing intelligent cardiovascular diagnostic
imaging technologies, today announced the upcoming presentation of
three LipiScan™-related scientific abstracts at the American
Heart Association Scientific Sessions 2010 (
AHA 2010), being held Nov. 13-17, 2010 at McCormick Place in
Chicago. The research being presented includes an oral abstract
session focused on cost effectiveness and screening advances, as
well as two abstract poster sessions involving InfraReDx’s research
in the area of lipid core plaque burden and its role in coronary
health. Additionally, the company will be exhibiting at booth #950
on Nov. 14-16.

InfraReDx recently launched the LipiScan IVUS Coronary Imaging
System, the world’s first and only intravascular imaging system
that combines and co-registers grayscale intravascular ultrasound
(IVUS) with the company’s proprietary near infrared (NIR)
spectroscopy lipid core plaque (LCP) detection technology, to
improve the safety and effectiveness of stenting procedures.

“The role of lipid core plaque in coronary artery disease
continues to be a topic of significant medical interest as
indicated by the AHA meeting program,” said James E. Muller, M.D.,
founder and chief executive officer of InfraReDx. “We are pleased
that the LipiScan IVUS system is now available for use by the
cardiology community. The LipiScan component of the multimodality
catheter provides a rapid and accurate means to identify lipid core
plaque in patients undergoing catheterization. Detection of these
plaques is of clinical importance because there is extensive
evidence indicating that these lipid core plaques are
‘complication-prone’ when stenting is performed. In addition, lipid
core plaques are suspected to be ‘vulnerable plaques’ that
cau

‘/>”/>

SOURCE